DOCSLIB.ORG

Do Vaccines Trigger Neurological Diseases? Multiple Sclerosis, Guillain- Barre Syndrome and Narcolepsy from Epidemiological Pers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Do Vaccines Trigger Neurological Diseases? Multiple Sclerosis, Guillain- Barre Syndrome and Narcolepsy from Epidemiological Pers Do vaccines trigger neurological diseases? Multiple sclerosis, Guillain- Barre syndrome and Narcolepsy from epidemiological perspective ESCMID eLibrary Dr Julia Stowe, Immunisation and Countermeasures, Public Health England ECCMID Sunday14© byApril 2019 16:00author-18:00, Hall B Cause or Coincidence? • No medical intervention is 100% safe so it is a balance of risk and benefit • Rare reactions are not picked up in trials • Vaccines are given to very large numbers so more opportunity to see rare reactions • More likely to see coincidental events after vaccines • May seem plausible on individual case basis due to temporal association • As disease disappears reactions may become more of a ESCMIDrisk to an individual than disease eLibrary 2 © by author Whooping cough cases and vaccine coverage England and Wales 1940-2006 200 Immunisation 180 introduced 80 160 140 120 40 Coverage 100 80 60 0 Notifications (thousands) Notifications 40 20 ESCMID0 eLibrary 1940 1950 1960 1970 1980 1990 2000 Year © by author Neurological conditions in temporal relationship to vaccines Biological Plausible • Acute Flaccid Paralysis and oral polio vaccine - risk 4 in 1,000,000 • Bells Palsy & influenza vaccine (nasal)- risk OR 84.0 • Bells Palsy & influenza vaccine (parenteral) - no effect • Aseptic meningitis & MMR- (Urabe mumps strain) – risk 1 in 12,000 doses • Febrile convulsions & MMR- risk 1 in 1200 doses Unsubstantiated & Unexpected • Neurological complications & whooping cough vaccine- no effect • Autism & MMR- no effect • Gait disturbance and MMR vaccine- no effect • Thiomersal and developmental delay - no effect • Guillain-Barre Syndrome • ESCMIDNarcolepsy eLibrary • Multiple Sclerosis 4 © by author Epidemiological Statistical Methods • Compare disease in vaccinated and unvaccinated- Odds ratio • Need to know if person truly vaccinated • Need to match on DOB- short age range in baby vaccines Case- coverage method • Vaccine coverage data • Matched on risk group, age • Reference date is first symptoms in case • Similar to a case control study with 1000’s of controls per individual. • Incidence of disease in vaccinated compared to unvaccinated • Need to have great number of confounder variables • Small unvaccinated population not representative • Unvaccinated truly not vaccinated ESCMID eLibrary• Case only methods- Self-controlled case series • Only use vaccinated cases 5 © by author Self-Controlled Cases-Series (SCCS) method • For each individual each day and event in the study period will fall inside or outside the risk period. • Pre specified risk period after vaccination • Unbiased ascertainment of cases in a given age group and study period and their vaccination details. vaccination Event Jan 01 Dec 01 risk period Compare risk of events in risk period to background RelativeESCMID incidence = Events inside risk periodeLibrary / days inside risk period . Events outside risk period / days outside risk period Farrington CP. Control without separate controls: evaluation of vaccine safety using case- 6 only methods.© Vaccine. 2004by May 7;22(15 author-16):2064-70 Which design to use? The design will depend on the precise question, data sources available, likely important confounding variables May be a trade off between the ideal and the practical Data sources….. Immunisation registries Linkage Disease registers Hospital Episode databases Individual Hospital data General Practice databases Health Maintenance data bases Prospective cohorts (e.g. whole birth cohorts followed up) TheESCMID best designs may vary – buteLibrary key to causality is consistency from well designed studies. © by author Neurological disease and vaccines • Common features: • Serious conditions • Rare • Aetiology and pathophysiology poorly understood • believed that immune stimulation plays a role in the conditions pathogenesis • Because of vaccines effect on the immune ESCMIDsystem it makes it biologicallyeLibrary plausible 8 © by author Multiple sclerosis & Hepatitis B vaccine • Mass vaccine campaign in France in 1994 • Few cases of MS reported within a few weeks of the vaccine in France • Hypothesis is that the vaccine could cause an acute autoimmune reaction in susceptible persons soon after administration • Response was not robust- no background rates in relevant population • Lead to mistrust of the vaccine • 1998 school based vaccine programme in France suspended as a precaution • ESCMIDMany studies since have demonstrated eLibrary no association © by author Hepatitis B vaccination and the putative risk of central demyelinating diseases -A systematic review and meta- analysis. MouchetJ, Salvo F, Raschi E, PoluzziE, Antonazzo IC, De Ponti F, BégaudB. Vaccine.2018 Mar 14;36(12):1548-1555. doi: 10.1016/j.vaccine.2018.02.036. Epub2018 Feb 15. ESCMID eLibrary • No evidence of association 10 © by author Guillain-Barré syndrome and vaccines • Commonest cause of acute neuromuscular paralysis in the developed world • Causes muscle weakness and sometimes paralysis • Can lead to respiratory failure – 10% fatality rate • Strongest evidence as vaccine reaction:1976 US swine influenza vaccine programme- this programme was subsequently suspended • Since remained as potential adverse event after vaccine • More recently linked to vaccines given in adolescence – when autoimmune disease often diagnosed - Influenza vaccines -ESCMIDVaccines given in adolescence eLibrary -HPV vaccine 11 © by author Guillain-Barré syndrome Meta-analysis of risk of GBS and flu vaccines Decreased risk Increased risk Decreased risk Increased risk Conclusion: the receipt of any influenza vaccine carried a small relative increased risk of 1.41 (1.20- 1.66) Two other meta-analysis found similar marginal statistical significance for seasonal vaccines- Dodd et al. RI=2.1 (1.1-3.4); SalmonESCMID et al. IRR=2.3 (1.4-4.0) eLibrary Pandemic vaccine: differences between countries- lower in US and Europe -Adjuvanted / unadjuvanted difference (England/US) 12 © by author GBS and flu-like illness General Practice Research Database (GPRD) 1990-2005 RESULTS from 775 GBS episodes Interval between influenza-like illness and GBS ESCMID eLibrary © by Stoweauthor et al, Am. J. Epidemiol. 2008, 169: 382 - 388 ESCMID eLibrary 14 © byFrom: Stoweauthor et al, Am. J. Epidemiol. 2008, 169: 382 - 388 Guillain-Barré syndrome and Influenza vaccines: Conclusions: • Small overall risk seen in the meta analysis • Slightly larger overall risk seen in pandemic season • Geographic differences seen • Mechanism may be multi factored: different vaccines used- adjuvanted/unadjuvanted other infections circulating Susceptibility to develop GBS • These small risks do not outweigh the risk getting GBS ESCMIDafter flu itself eLibrary • More work to be done! 15 © by author Is there a risk of GBS after HPV vaccine? • HPV vaccine given at age when autoimmune disorders diagnosed • A French study reported a signal for GBS among a group of other conditions • GBS cases identified in hospital discharge database for England (HES) • Primary care practitioners (GPs) contacted for the vaccination history • GP asked to confirm GBS diagnosis- provide an onset date and send supporting documentation • Diagnosis certainty levels were assigned – confirmed, probable or not • GBS index date derived from the earliest date from GP questionnaire / ESCMIDsupporting documentation / admission eLibrary date (HES) 16 © by author No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self- controlled case-series study in England. Vaccine. 2017 Mar 23;35(13):1729-1732. Analysis (total episodes) Risk period Episodes in the RI (95% CI) (days) risk period Primary (101) 0-91 9 1.04 (0.47-2.28) Alternative risk windows (101) 92-183 5 0.78 (0.27-2.21) 184-365 10 1.41 (0.61-3.22) 0-183 14 0.83 (0.41-1.69) 0-365 24 1.10 (0.57-2.14) Just confirmed cases (79) 0-91 9 1.26 (0.55-2.92) The quadrivalent vaccine Gardasil ® (15) 0-91 4 1.61 (0.39-6.54) The ESCMIDbivalent vaccine 0- 91 eLibrary5 0.84 (0.30-2.34) Cervarix ® (86) 17 © by author Narcolepsy and pandemic influenza vaccine, Pandemrix Finland: High Coverage: 75% of those Partinen et al under 19 years received the Plos One Pandemrix vaccine March 2012 Ecological study ESCMID eLibrary © by author WHO Global Advisory Committee on Vaccine Safety - April 2011 “An increased risk of narcolepsy has not been observed in association with the use of any vaccines whether against influenza or other diseases in the past. Even at this stage, it does not appear that narcolepsy following vaccination against pandemic influenza is a general worldwide phenomenon, as no excess of narcolepsy has been reported from several other European states where Pandemrix was used, or from Canada where a pandemic vaccine similar to pandemrix was used. This complicates interpretation of the findings in Finland and Sweden. It seems likely that some as yet unidentified ESCMIDadditional factor was operating eLibrary in Sweden and Finland.” © by author Narcolepsy and pandemic influenza vaccine Google searches for “narcolepsy” or “narkolepsi” from UK and Sweden *Relative scaling is based on the average traffic 25 August 2010 - 20 fold st 20 increase when 1 cases reported UK Sweden 15 Dec 2011- small peak coincided 10 with BBC documentary 5 ESCMID eLibrary 0 00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy00-yy © by author Narcolepsy and pandemic influenza vaccine
Load more

Recommended publications
  • Mercury and Vaccinations
    MERCURYMERCURY ANDAND VACCINESVACCINES FACT SHEET, OCTOBER 2006 What is the concern about mercury in vaccines? Thimerosal, also known as thiomersal, is a preservative used in a number of biological and pharmaceutical products, including some flu and many multi-dose vaccines used for child immunisation. Mercury makes up approximately 50% of the weight of thimerosal in the organic form of ethylmercury. Thimerosal has been added to products to help prevent the growth of microbes since the 1930s. As more has become known about the effects of mercury on human health, the use of thimerosal in vaccines became an issue of increasing concern. Over the years, with more and more childhood vaccinations recommended or required, the amount of mercury to which infants and young children are being exposed has signifi- cantly increased. While there were no toxic effects reported in the first study of thimerosal use in humans, published in 1931, the study was not specifically designed to examine toxicity and was flawed in a number of other ways.1 Studies of any potential effects of thimerosal exposure in humans are ongoing and no general scientific consensus currently exists. Questions have particularly arisen around a possible connection between thimerosal and autism. Additionally, research is being conducted into the relationship between mercury exposure and Alzheimer’s disease. In 2004, a statement from the European Agency for the Evaluation of Medicinal Products (EMEA) noted that new toxicity studies demonstrate that ethylmercury is less toxic than methylmercury, the form people ingest by eating some types of fish.2 The following year, the report of the Immunisation Safety Review Committee produced by the US Institute of Medicine found again that reviewed evidence “favours a rejection of a causal relationship between thimerosal-containing vaccines and autism.”3 Yet, others have suggested that new toxicological data shows that there could be a plausible connection between thi- merosal and neurological effects in animals and humans.
    [Show full text]
  • Gavi's Vaccine Investment Strategy
    Gavi’s Vaccine Investment Strategy Deepali Patel THIRD WHO CONSULTATION ON GLOBAL ACTION PLAN FOR INFLUENZA VACCINES (GAP III) Geneva, Switzerland, 15-16 November 2016 www.gavi.org Vaccine Investment Strategy (VIS) Evidence-based approach to identifying new vaccine priorities for Gavi support Strategic investment Conducted every 5 years decision-making (rather than first-come- first-serve) Transparent methodology Consultations and Predictability of Gavi independent expert advice programmes for long- term planning by Analytical review of governments, industry evidence and modelling and donors 2 VIS is aligned with Gavi’s strategic cycle and replenishment 2011-2015 Strategic 2016-2020 Strategic 2021-2025 period period 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 RTS,S pilot funding decision VIS #1 VIS #2 VIS #3 MenA, YF mass campaigns, JE, HPV Cholera stockpile, Mid 2017 : vaccine ‘long list’ Rubella, Rabies/cholera studies, Oct 2017 : methodology Typhoid Malaria – deferred Jun 2018 : vaccine shortlist conjugate Dec 2018 : investment decisions 3 VIS process Develop Collect data Develop in-depth methodology and Apply decision investment decision framework for cases for framework with comparative shortlisted evaluation analysis vaccines criteria Phase I Narrow long list Phase II Recommend for Identify long list to higher priority Gavi Board of vaccines vaccines approval of selected vaccines Stakeholder consultations and independent expert review 4 Evaluation criteria (VIS #2 – 2013) Additional Health Implementation
    [Show full text]
  • Mmrv Vaccine
    VACCINE INFORMATION STATEMENT (Measles, Mumps, Many Vaccine Information Statements are available in Spanish and other languages. MMRV Vaccine Rubella and See www.immunize.org/vis Varicella) Hojas de información sobre vacunas están disponibles en español y en muchos otros What You Need to Know idiomas. Visite www.immunize.org/vis These are recommended ages. But children can get the Measles, Mumps, Rubella and second dose up through 12 years as long as it is at least 1 Varicella 3 months after the first dose. Measles, Mumps, Rubella, and Varicella (chickenpox) can be serious diseases: Children may also get these vaccines as 2 separate shots: MMR (measles, mumps and rubella) and Measles varicella vaccines. • Causes rash, cough, runny nose, eye irritation, fever. • Can lead to ear infection, pneumonia, seizures, brain 1 Shot (MMRV) or 2 Shots (MMR & Varicella)? damage, and death. • Both options give the same protection. Mumps • One less shot with MMRV. • Causes fever, headache, swollen glands. • Children who got the first dose as MMRV have • Can lead to deafness, meningitis (infection of the brain had more fevers and fever-related seizures (about and spinal cord covering), infection of the pancreas, 1 in 1,250) than children who got the first dose as painful swelling of the testicles or ovaries, and, rarely, separate shots of MMR and varicella vaccines on death. the same day (about 1 in 2,500). Rubella (German Measles) Your doctor can give you more information, • Causes rash and mild fever; and can cause arthritis, including the Vaccine Information Statements for (mostly in women). MMR and Varicella vaccines.
    [Show full text]
  • HPV Vaccine Safety - Vaccine Safety
    CDC - HPV Vaccine Safety - Vaccine Safety Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options CDC Home CDC 24/7: Saving Lives. Protecting People.™ Search The CDC Vaccine Safety Vaccine Safety Vaccines Safety Basics Diphtheria, Tetanus, and Pertussis Vaccines: DTaP, Td, and Tdap Haemophilus Influenzae Type B (Hib) Hib Summary Human Papillomavirus (HPV) FAQs about HPV Vaccine Safety FAQ: Gardasil Vaccine recall JAMA Report Summary Information from FDA and CDC on Gardasil and its Safety (Archived) Measles, Mumps, Rubella (MMR) MMR Vaccine Safety Studies Measles, Mumps, Rubella, Varicella (MMRV) Information on the VSD MMRV Vaccine Safety Study MMRV Vaccine Safety Studies MMRV and Febrile Seizures Rotavirus Varicella Addressing Common Concerns Adjuvants Autism Vaccine not associated with autism CDC Statement: 2004 Pediatrics Paper CDC Statement on Pandemrix Fainting (Syncope) FAQs about Fainting (Syncope) After Vaccination Childhood Vaccines and Febrile Seizures Influenza Season 2012-2013 Influenza Season 2010-2011 GBS GBS and Menactra Meningococcal Vaccine FAQs about GBS and Menactra Meningococcal Vaccine IOM Assessment of Studies on Childhood Immunization Schedule IOM Report on Adverse Effects of Vaccines Pregnancy and Influenza Vaccine Safety Sudden Infant Death Syndrome (SIDS) Thimerosal http://www.cdc.gov/vaccinesafety/vaccines/HPV/index.html[10/13/2014 5:59:00 PM] CDC - HPV Vaccine Safety - Vaccine Safety CDC Study on Thimerosal and Risk of Autism
    [Show full text]
  • The Hepatitis B Vaccine Is the Most Widely Used Vaccine in the World, with Over 1 Billion Doses Given
    Hepatitis B Vaccine Protect Yourself and Those You Love What is Hepatitis B? Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus (HBV), which attacks liver cells and can lead to liver failure, cirrhosis (scarring), or liver cancer later in life. The virus is transmitted through direct contact with infected blood and bodily fluids, and from an infected woman to her newborn at birth. Is there a safe vaccine for hepatitis B? YES! The good news is that there is a safe and effective vaccine for hepatitis B. The vaccine is a series, typically given as three shots over a six-month period that will provide a lifetime of protection. You cannot get hepatitis B from the vaccine – there is no human blood or live virus in the vaccine. The hepatitis B vaccine is the most widely used vaccine in the world, with over 1 billion doses given. The hepatitis B vaccine is the first "anti-cancer" vaccine because it can help prevent liver cancer! Who should be vaccinated against hepatitis B? The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) recommend the hepatitis B vaccine for all newborns and children up to 18 years of age, and all high-risk adults. All infants should receive the first dose of the vaccine in the delivery room or in the first 24 hours of life, preferably within 12 hours. (CDC recommends the first dose within 12 hours vs. the WHO recommendation of 24 hours.) The HBV vaccine is recommended to anyone who is at high risk of infection.
    [Show full text]
  • Engerix-B Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME ENGERIX-B 20 micrograms/mL, suspension for injection. ENGERIX-B paediatric 10 micrograms/0.5 mL, suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ENGERIX-B paediatric dose: 10 microgram (µg) dose vaccine 1 dose (0.5 mL) contains: Hepatitis B surface antigen 1, 2 10 micrograms 1Adsorbed on aluminium hydroxide, hydrated Total: 0.25 milligrams Al3+ 2Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology ENGERIX-B: 20 microgram (µg) dose vaccine 1 dose (1 mL) contains: Hepatitis B surface antigen1, 2 20 micrograms 1Adsorbed on aluminium hydroxide, hydrated Total: 0.50 milligrams Al3+ 2Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology The vaccine is highly purified, and meets the WHO requirements for recombinant hepatitis B vaccines. No substances of human origin are used in its manufacture. For the full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Suspension for injection. ENGERIX-B is a turbid white suspension. Upon storage, a fine white deposit with a clear colourless supernatant may be observed. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications ENGERIX-B is indicated for active immunisation against hepatitis B virus infection. As part of the national immunisation schedule, the New Zealand Ministry of Health* recommend all infants, unvaccinated children up to the age of 16 years, and household and sexual contacts of known hepatitis B carriers receive a primary course of vaccination against hepatitis B. 1 Immunisation is also recommended for seronegative persons who are at substantial risk and have been demonstrated or judged to be susceptible to the hepatitis B virus (HBV).
    [Show full text]
  • COVID-19 and Cancer: from Basic Mechanisms to Vaccine Development Using Nanotechnology
    International Immunopharmacology 90 (2021) 107247 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology Hyun Jee Han a,*, Chinekwu Nwagwu b, Obumneme Anyim c, Chinedu Ekweremadu d, San Kim e a University College London, Department of Neonatology, United Kingdom b Department of Pharmaceutics, University of Nigeria Nsukka, Nigeria c Department of Internal Medicine, University of Nigeria Teaching Hospital Ituku-Ozalla, Enugu, Nigeria d Department of Pharmaceutics and Pharmaceutical Technology Enugu State University of Science and Technology, Nigeria e Basildon and Thurrock University Hospital, United Kingdom ARTICLE INFO ABSTRACT Keywords: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV- COVID-19 2), is a global pandemic which has induced unprecedented ramifications,severely affecting our society due to the Cancer long incubation time, unpredictably high prevalence and lack of effective vaccines. One of the interesting notions Vaccine development is that there is an association between COVID-19 and cancer. Cancer patients seem to exhibit exacerbated Pharmaceutics conditions and a higher mortality rate when exposed to the virus. Therefore, vaccines are the promising solution Nanotechnology to minimise the problem amongst cancer patients threatened by the new viral strains. However, there are still limitations to be considered, including the efficacy of COVID vaccines for immunocompromised individuals, possible interactions between the vaccine and cancer, and personalised medicine. Not only to eradicate the pandemic, but also to make it more effective for immunocompromised patients who are suffering from cancer, a successful vaccine platform is required through the implementation of nanotechnology which can also enable scalable manufacturing and worldwide distribution along with its faster and precise delivery.
    [Show full text]
  • Package Insert
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------------- CONTRAINDICATIONS ------------------------------------- These highlights do not include all the information needed to use ® • History of severe allergic reactions (e.g., anaphylaxis) to egg proteins, or any FLUVIRIN (Influenza Virus Vaccine) safely and effectively. See full ® ® component of FLUVIRIN , or life-threatening reactions to previous influenza prescribing information for FLUVIRIN . vaccinations. (4.1, 11) FLUVIRIN® (Influenza Virus Vaccine) Suspension for Intramuscular Injection ---------------------- WARNINGS AND PRECAUTIONS ------------------------------ 2017-2018 Formula • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior Initial US Approval: 1988 influenza vaccine, the decision to give FLUVIRIN® should be based on -------------------------- INDICATIONS AND USAGE ---------------------------------- careful consideration of the potential benefits and risks. (5.1) ® • FLUVIRIN is an inactivated influenza virus vaccine indicated for active • Immunocompromised persons may have a reduced immune response to immunization of persons 4 years of age and older against influenza disease FLUVIRIN®. (5.2) caused by influenza virus subtypes A and type B contained in the vaccine (1). • The tip caps of the FLUVIRIN® prefilled syringes may contain natural rubber • FLUVIRIN® is not indicated for children less than 4 years of age because latex which may cause allergic reactions in latex sensitive individuals. there is evidence of diminished immune response
    [Show full text]
  • NHSGGC COVID Vaccine Faqs for Health and Social Care Staff Version 06 12/01/21
    NHSGGC COVID Vaccine FAQs for Health and Social Care Staff Version 06 12/01/21 Link to Green Book Chapter on COVID Vaccine MHRA vaccine approval JCVI recommendations CMO Letter COVID Vaccination Programme These FAQs relate to the Pzifer/BioNTech and AstraZeneca vaccine COVID-19 vaccine The FAQs will be frequently updated as new information becomes available Any printed version will quickly be outdated, always check the NHSGGC webpage for the most up-to-date advice Sections in this document 1. Vaccine Details 2. Current illness and COVID vaccine 3. Flu Vaccine 4. I am immunosuppressed 5. I have previously had a positive COVID test result 6. I have taken part in a COVID vaccine trial 7. Infection Control 8. Nursing Homes 9. Pregnancy and Breastfeeding 10. Allergies and anaphylaxis and other medications 11. Staff Queries – General 12. COVID Vaccines and other vaccines 13. How to become a vaccinator 14. Appointments NHSGGC COVID Vaccine FAQs for Health and Social Care Staff Version 06 12/01/21 Section 1: Vaccine Details Are they live vaccines? No. Neither the Pfizer-BioNTech vaccine nor the AstraZeneca (AZ) vaccine are live vaccines. The AZ vaccine uses an adenovirus, but as it cannot replicate it is not a live vaccine. How is the COVID-19 vaccine given? You will be given an injection in your upper arm. You will need two doses, the second will be offered 12 weeks after the first dose. During your vaccination, strict infection prevention and control measures will be in place. Will a vaccine booster be required? The schedule requires two doses.
    [Show full text]
  • Vaccines for Preteens
    | DISEASES and the VACCINES THAT PREVENT THEM | INFORMATION FOR PARENTS Vaccines for Preteens: What Parents Should Know Last updated JANUARY 2017 Why does my child need vaccines now? to get vaccinated. The best time to get the flu vaccine is as soon as it’s available in your community, ideally by October. Vaccines aren’t just for babies. Some of the vaccines that While it’s best to be vaccinated before flu begins causing babies get can wear off as kids get older. And as kids grow up illness in your community, flu vaccination can be beneficial as they may come in contact with different diseases than when long as flu viruses are circulating, even in January or later. they were babies. There are vaccines that can help protect your preteen or teen from these other illnesses. When should my child be vaccinated? What vaccines does my child need? A good time to get these vaccines is during a yearly health Tdap Vaccine checkup. Your preteen or teen can also get these vaccines at This vaccine helps protect against three serious diseases: a physical exam required for sports, school, or camp. It’s a tetanus, diphtheria, and pertussis (whooping cough). good idea to ask the doctor or nurse every year if there are any Preteens should get Tdap at age 11 or 12. If your teen didn’t vaccines that your child may need. get a Tdap shot as a preteen, ask their doctor or nurse about getting the shot now. What else should I know about these vaccines? These vaccines have all been studied very carefully and are Meningococcal Vaccine safe.
    [Show full text]
  • Considerations for Causality Assessment of Neurological And
    Occasional essay J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2021-326924 on 6 August 2021. Downloaded from Considerations for causality assessment of neurological and neuropsychiatric complications of SARS- CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder Matt Butler ,1 Arina Tamborska,2,3 Greta K Wood,2,3 Mark Ellul,4 Rhys H Thomas,5,6 Ian Galea ,7 Sarah Pett,8 Bhagteshwar Singh,3 Tom Solomon,4 Thomas Arthur Pollak,9 Benedict D Michael,2,3 Timothy R Nicholson10 For numbered affiliations see INTRODUCTION More severe potential adverse effects in the open- end of article. The scientific community rapidly responded to label phase of vaccine roll- outs are being collected the COVID-19 pandemic by developing novel through national surveillance systems. In the USA, Correspondence to SARS- CoV-2 vaccines (table 1). As of early June Dr Timothy R Nicholson, King’s roughly 372 adverse events have been reported per College London, London WC2R 2021, an estimated 2 billion doses have been million doses, which is a lower rate than expected 1 2LS, UK; timothy. nicholson@ administered worldwide. Neurological adverse based on the clinical trials.6 kcl. ac. uk events following immunisation (AEFI), such as In the UK, adverse events are reported via the cerebral venous sinus thrombosis and demyelin- MB and AT are joint first Coronavirus Yellow Card reporting website. As of ating episodes, have been reported. In some coun- authors. early June 2021, approximately 250 000 Yellow tries, these have led to the temporary halting of BDM and TRN are joint senior Cards have been submitted, equating to around authors.
    [Show full text]
  • Vaccine Information for PARENTS and CAREGIVERS
    NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES Division of the National Health Laboratory Service VACCINE INFOR MATION FOR PARENTS & CAREGIVERS First Edition November 2016 Editors-in-Chief Nkengafac Villyen Motaze (MD, MSc, PhD fellow), Melinda Suchard (MBBCh, FCPath (SA), MMed) Edited by: Cheryl Cohen, (MBBCh, FCPath (SA) Micro, DTM&H, MSc (Epi), Phd) Lee Baker, (Dip Pharm) Lucille Blumberg, (MBBCh, MMed (Micro) ID (SA) FFTM (RCPS, Glasgow) DTM&H DOH DCH) Published by: Ideas Wise and Wonderful (IWW) for National Institute for Communicable Diseases (NICD) First Edition: Copyright © 2016 Contributions by: Clement Adu-Gyamfi (BSc Hons, MSc), Jayendrie Thaver (BSc), Kerrigan McCarthy, (MBBCh, FCPath (SA), DTM&H, MPhil (Theol) Kirsten Redman (BSc Hons), Nishi Prabdial-Sing (PhD), Nonhlanhla Mbenenge (MBBCh, MMED) Philippa Hime (midwife), Vania Duxbury (BSc Hons), Wayne Howard (BSc Hons) Acknowledgments: Amayeza, Vaccine Information Centre (http://www.amayeza-info.co.za/) Centre for Communicable Diseases Fact Sheets (http://www.cdc.gov/vaccines/hcp/vis/) World Health Organization Fact Sheets (http://www.who.int/mediacentre/factsheets/en/) National Department of Health, South Africa (http://www.health.gov.za/) Disclaimer This book is intended as an educational tool only. Information may be subject to change as schedules or formulations are updated. Summarized and simplified information is presented in this booklet. For full prescribing information and contraindications for vaccinations, please consult individual package inserts. There has been
    [Show full text]